About: Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $78.14 (-1.71%)
ORKA NASDAQ Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. share price
ORKA price activity
Último preço
$ 76,910
Variação (24h)
-2,59 USD (-3,26%)
Volume
101.82K
Volume (média 4 sem.)
-
Abertura
$ 78,51
Variação do dia
$ 76,91 - $ 80,19
Fechamento anterior
$ 79,50
Último negócio
08 Oct, 2:23 pm GMT+0
Atrasado
08 Oct, 2:23 pm GMT+0
ORKA price performance
Atrasado
08 Oct, 2:23 pm GMT+0
quote.marketSignals